CCL5 increases lung cancer migration via PI3K, Akt and NF-κB pathways

CMUR > China Medical University Beikang Hospital > Journal articles > Item 310903500/3227

Please use this identifier to cite or link to this item: http://ir.cmu.edu.tw/ir/handle/310903500/3227

Title:	CCL5 increases lung cancer migration via PI3K, Akt and NF-κB pathways
Authors:	黃俊寅(Chun-Yin Huang);馮逸卿(Yi-Chin Fong);李俊億(Chun-Yi Lee);陳孟意(Meng-Yi Chen);蔡筱琪(Hsiao-Chi Tsai);許弘昌(Horng-Chaung Hsu);湯智昕(Tang Chih-Hsin)*
Contributors:	北港醫院骨科
Keywords:	CCL5;Lung cancer;Migration;Akt;PI3K
Date:	2009-03
Issue Date:	2009-08-20 18:09:18 (UTC+8)
Abstract:	CCL5 (previously called RANTES) is in the CC-chemokine family and plays a crucial role in the migration and metastasis of human cancer cells. Besides, integrins are the major adhesive molecules in mammalian cells. Here we found CCL5 increased the migration and cell surface expression of αvβ3 integrin in human lung cancer cells (A549 cells). CCL5 stimulation increased phosphorylation of the p85α subunit of phosphatidylinositol 3-kinase (PI3K) and serine 473 of Akt. Also, we found that PI3K inhibitor (Ly294002) or Akt inhibitor suppressed CCL5-induced migration activities and integrin expression of A549 cells. Transfection of cells with p85 or Akt mutant also reduced CCL5-mediated cancer migration. In addition, treatment of A549 cells with CCL5 induced IκB kinase α/β (IKK α/β) phosphorylation, IκB phosphorylation, p65 Ser536 phosphorylation, and κB-luciferase activity. Furthermore, the CCL5-mediated increases in p65 Ser536 phosphorylation were inhibited by Ly294002 and Akt inhibitor. Taken together, our results suggest that CCL5 acts through PI3K/Akt, which in turn activates IKKα/β and NF-κB, resulting in the activation of αvβ3 integrin and contributing to the migration of human lung cancer cells.
Relation:	BIOCHEMICAL PHARMACOLOGY 77(5):794~803
Appears in Collections:	[China Medical University Beikang Hospital] Journal articles

Files in This Item:

File	Size	Format
	58Kb	Unknown	838	View/Open

Loading...